Lennar's consensus analyst price target has recently edged down from $129.07 to $127.50. This reflects a modest reduction of ...

Summit Therapeutics (SMMT) announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso (AKESF), ...